SCHEDULE 13G/A: Frazier Life Sciences Amends Adverum Biotech Stake

Frazier Life Sciences funds updated their beneficial ownership in Adverum Biotechnologies, Inc., with Frazier Life Sciences Public Fund, L.P. holding 19.4%.

Summary

• Frazier Life Sciences Public Fund, L.P. reported beneficial ownership of 4,288,949 shares of Adverum Biotechnologies, Inc. common stock, representing 19.4% of the class.
• This ownership includes shares acquired from Frazier Life Sciences Public Overage Fund, L.P. pursuant to a merger.
• Frazier Life Sciences X, L.P. reported beneficial ownership of 216,964 shares, representing 1.0% of the class.
• Frazier Life Sciences XI, L.P. reported beneficial ownership of 504,849 shares, representing 2.3% of the class.
• Frazier Life Sciences XII, L.P. reported beneficial ownership of 522,768 shares, representing 2.4% of the class.
• The percentages are calculated based on 22,077,467 shares of Common Stock outstanding on November 7, 2025, as reported in Adverum Biotechnologies, Inc.'s Quarterly Report on Form 10-Q filed on November 12, 2025.
• The reporting persons certified that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing indicates a stable, significant institutional ownership by a specialized life sciences investor, which is generally a positive signal of confidence. However, it does not contain new operational or financial news from the company itself, thus limiting its direct impact on sentiment beyond confirming existing investor interest.

Positives

• A significant institutional investor, Frazier Life Sciences, maintains a substantial stake in Adverum Biotechnologies, Inc., with its largest fund holding 19.4% of the common stock.
• The continued presence of a specialized life sciences investor as a major shareholder indicates ongoing confidence in the company.

Negatives

• No negative information is presented in this beneficial ownership disclosure.

Risks

• No specific risks related to Adverum Biotechnologies, Inc. are disclosed in this Schedule 13G/A filing, which focuses solely on beneficial ownership.

Future Outlook

This Schedule 13G/A filing does not contain forward-looking statements or guidance regarding Adverum Biotechnologies, Inc.'s future outlook, as it is solely an ownership disclosure.

Management Comments

• No direct quotes or paraphrased statements from Adverum Biotechnologies, Inc. management are included in this beneficial ownership filing.

Industry Context

This filing reflects the ongoing investment activity of specialized life sciences funds, such as Frazier Life Sciences, in biotechnology companies like Adverum Biotechnologies. Such significant stakes by institutional investors are common in the biotech sector, where long-term capital is often required for drug development and commercialization.

Comparison to Industry Standards

• Not applicable. This filing is an ownership disclosure and does not contain performance metrics or operational results that can be compared to industry benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially signaling continued confidence in the company.
• Management: Awareness of a large, stable shareholder base from a specialized life sciences investment group.

Next Steps

• No specific future actions, events, or milestones for Adverum Biotechnologies, Inc. are mentioned in this beneficial ownership filing.

Key Dates

Recommendation

This Schedule 13G/A filing is a routine disclosure of beneficial ownership by a group of institutional investors. While the continued significant stake by Frazier Life Sciences funds is a positive indicator of investor confidence in Adverum Biotechnologies, the filing itself does not contain new operational, financial, or strategic information that would warrant a change in investment recommendation. Investors should continue to hold based on the company's fundamentals and broader market conditions, rather than this specific ownership update.

Keywords

Adverum Biotechnologies, ADVM, Frazier Life Sciences, Schedule 13G/A, Beneficial Ownership, Institutional Investor, Biotechnology, SEC Filing, Equity Stake